Lexaria Bioscience Corp (LEXX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) has a cash flow conversion efficiency ratio of -0.376x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.64 Million) by net assets ($4.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Lexaria Bioscience Corp stock valuation for the company's overall valuation and market capitalisation.
Lexaria Bioscience Corp - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lexaria Bioscience Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexaria Bioscience Corp ranked by their cash flow conversion efficiency. Explore LEXX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noronex Ltd
AU:NRX
|
-2.126x |
|
RWS Holdings PLC
LSE:RWS
|
0.027x |
|
ARK Resources Bhd
KLSE:7007
|
0.552x |
|
ROKMASTER Resources Corp
V:RKR
|
0.203x |
|
TROY MINERALS INC.
F:VJ3
|
N/A |
|
Johan Holdings Bhd
KLSE:3441
|
-0.032x |
|
Elaia Investment Spain Socimi SA
MC:YEIS
|
-0.010x |
|
Bindi Metals Ltd
AU:BIM
|
-0.099x |
Annual Cash Flow Conversion Efficiency for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual cash flow conversion efficiency of Lexaria Bioscience Corp from 2005 to 2025. View LEXX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.60 Million | $-10.45 Million | -4.015x | -520.13% |
| 2024-08-31 | $7.66 Million | $-4.96 Million | -0.647x | +70.49% |
| 2023-08-31 | $2.68 Million | $-5.88 Million | -2.194x | -243.26% |
| 2022-08-31 | $7.63 Million | $-4.88 Million | -0.639x | -109.32% |
| 2021-08-31 | $13.06 Million | $-3.99 Million | -0.305x | +71.05% |
| 2020-08-31 | $2.48 Million | $-2.62 Million | -1.055x | +12.57% |
| 2019-08-31 | $2.49 Million | $-3.01 Million | -1.207x | -14.45% |
| 2018-08-31 | $2.39 Million | $-2.52 Million | -1.054x | -88.77% |
| 2017-08-31 | $2.77 Million | $-1.55 Million | -0.559x | +92.58% |
| 2016-08-31 | $87.76K | $-660.86K | -7.531x | -229.41% |
| 2015-08-31 | $656.60K | $-1.50 Million | -2.286x | -1594.78% |
| 2014-08-31 | $2.10 Million | $321.00K | 0.153x | 0.00% |
| 2013-08-31 | $2.10 Million | $321.00K | 0.153x | +6.02% |
| 2012-08-31 | $2.23 Million | $321.00K | 0.144x | +182.41% |
| 2011-08-31 | $2.66 Million | $135.94K | 0.051x | +11.09% |
| 2010-08-31 | $2.39 Million | $109.84K | 0.046x | +130.70% |
| 2009-08-31 | $2.21 Million | $-330.34K | -0.150x | -913.10% |
| 2008-08-31 | $2.46 Million | $-36.40K | -0.015x | -272.88% |
| 2007-08-31 | $3.39 Million | $29.04K | 0.009x | +102.76% |
| 2006-08-31 | $704.55K | $-218.56K | -0.310x | -120.33% |
| 2005-08-31 | $1.09 Million | $-153.38K | -0.141x | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more